© 2023 MJH Life Sciences and Urology Times. All rights reserved.
© 2023 MJH Life Sciences™ and Urology Times. All rights reserved.
January 27, 2023
"I think what you're going to see is more of the urologic end points, the different cancers, especially prostate cancer," says Mark Moyad, MD, MPH.
January 26, 2023
FACT-RNT is the first tool to measure patient reported outcomes associated with radionuclide therapy for prostate cancer.
The double-blind phase 3 KEYNOTE-991 trial had enrolled 1251 patients.
January 24, 2023
“We need to do better, and men in America deserve a better chance at long-term, good outcomes from their prostate cancer discovery,” says Michael S. Cookson, MD, MMHC.
January 23, 2023
“So many patients with prostate cancer qualify for genetic testing, but it's currently underutilized,” says Stacy Loeb, MD, MSc.
January 20, 2023
“The benefits can be reaped by the vast majority of patients and because we're really undertreating these patients, we need to make a conscious effort to overcome whatever barriers are facing us,” says Alicia Morgans, MD, MPH.
January 19, 2023
“If outcomes are improved for patients who take this combination — or in patients whose cancer is still progressing after being treated with hormone-based chemotherapy alone — this could be a big step forward in caring for these patients," says Moshe Ornstein, MD, MA.
“Vertebral fragility fractures are often asymptomatic and overlooked but are known to decrease quality of life, and can also affect mortality,” the authors wrote.
January 18, 2023
Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.
Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.